A single-institution evaluation of factors important in fallopian tube carcinoma recurrence and survival

International Journal of Gynecological Cancer

Volumn 21, Issue 7, 2011, Pages 1232-1240

  Shamshirsaz, Alireza A ^a   Buekers, Thomas ^b   DeGeest, Koen ^b   Bender, David ^b   Zamba, Gideon ^c   Goodheart, Michael J ^b  

^a UNIVERSITY OF IOWA   (United States)

^b UNIVERSITY OF IOWA HOSPITALS AND CLINICS   (United States)

^c UNIVERSITY OF IOWA   (United States)

Author keywords

Fallopian tube carcinoma; Laterality; Prognostic factors; Survival

Indexed keywords

CA 125 ANTIGEN;

ABDOMINAL CANCER; ADULT; ARTICLE; CANCER LOCALIZATION; CANCER PATIENT; CANCER PROGNOSIS; CANCER RECURRENCE; CANCER SIZE; CANCER STAGING; CANCER SURVIVAL; CLINICAL ARTICLE; CYTOREDUCTIVE SURGERY; DISEASE ASSOCIATION; FEMALE; FOLLOW UP; HUMAN; INTERNATIONAL FEDERATION OF GYNECOLOGY AND OBSTETRICS STAGE; MEDICAL RECORD REVIEW; PELVIS CANCER; PRIORITY JOURNAL; SMOKING; UTERINE TUBE CARCINOMA; AGED; CARCINOMA; KAPLAN MEIER METHOD; MIDDLE AGED; MORTALITY; PROGNOSIS; RETROSPECTIVE STUDY; TUMOR RECURRENCE; UNITED STATES; UTERINE TUBE TUMOR;

ADULT; AGED; AGED, 80 AND OVER; CARCINOMA; FALLOPIAN TUBE NEOPLASMS; FEMALE; HUMANS; KAPLAN-MEIER ESTIMATE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; PROGNOSIS; RETROSPECTIVE STUDIES; UNITED STATES;

EID: 84856072124     PISSN: 1048891X     EISSN: 15251438     Source Type: Journal    
DOI: 10.1097/IGC.0b013e318220fc46     Document Type: Article

References (47)

1. Peters WA 3rd, Andersen WA, Hopkins MP, et al. Prognostic features of carcinoma of the fallopian tube. Obstet Gynecol. 1988;71:757-762.
2. Goodman MT, Shvetsov YB. Incidence of ovarian, peritoneal, and fallopian tube carcinomas in the United States, 1995-2004. Cancer Epidemiol Biomarkers Prev. 2009;18:132-139.
3. Riska A, Leminen A, Pukkala E. Sociodemographic determinants of incidence of primary fallopian tube carcinoma, Finland 1953-97. Int J Cancer. 2003;104:643-645. (Pubitemid 36337266)
4. Morgan MA, Darcy KM, Rose PG, et al. Paclitaxel poliglumex and carboplatin as first-line therapy in ovarian, peritoneal or fallopian tube cancer: a phase I and feasibility trial of the Gynecologic Oncology Group. Gynecol Oncol. 2008;110:329-335.
5. Rocereto TF, Brady WE, Shahin MS, et al. A phase II evaluation of mifepristone in the treatment of recurrent or persistent epithelial ovarian, fallopian or primary peritoneal cancer: a Gynecologic Oncology Group study. Gynecol Oncol. 2010;116:332-334.
6. Wethington SL, Herzog TJ, Seshan VE, et al. Improved survival for fallopian tube cancer: a comparison of clinical characteristics and outcome for primary fallopian tube and ovarian cancer. Cancer. 2008;113:3298-3306.
7. Shaw PA, Rouzbahman M, Pizer ES, et al. Candidate serous cancer precursors in fallopian tube epithelium of BRCA1/2 mutation carriers. Mod Pathol. 2009;22:1133-1138.
8. Crum CP. Intercepting pelvic cancer in the distal fallopian tube: theories and realities. Mol Oncol. 2009;3:165-170.
9. Przybycin CG, Kurman RJ, Ronnett BM, et al. Are all pelvic (nonuterine) serous carcinomas of tubal origin? Am J Surg Pathol. 2010;34:1407-1416.
10. McCluggage WG. Uterine carcinosarcomas (malignant mixed Mullerian tumors) are metaplastic carcinomas. Int J Gynecol Cancer. 2002;12:687-690. (Pubitemid 35388035)
11. Moritani S, Moriya T, Kushima R, et al. Ovarian carcinoma recurring as carcinosarcoma. Pathol Int. 2001;51:380-384. (Pubitemid 32589027)
12. Toyoshima M, Akahira J, Matsunaga G, et al. Clinical experience with combination paclitaxel and carboplatin therapy for advanced or recurrent carcinosarcoma of the uterus. Gynecol Oncol. 2004;94:774-778. (Pubitemid 39194474)
13. Roberts JA, Lifshitz S. Primary adenocarcinoma of the fallopian tube. Gynecol Oncol. 1982;13:301-308. (Pubitemid 12090248)
14. Hu CY, Taymor ML, Hertig AT. Primary carcinoma of the fallopian tube. Am J Obstet Gynecol. 1950;59:58-67, illust.
15. Sedlis A. Primary carcinoma of the fallopian tube. Obstet Gynecol Surv. 1961;16:209-226.
16. Pettersson F. Staging rules for gestational trophoblastic tumors and fallopian tube cancer. Acta Obstet Gynecol Scand. 1992;71:224-225.
17. McGuire WP, Hoskins WJ, Brady MF, et al. Assessment of dose-intensive therapy in suboptimally debulked ovarian cancer: a Gynecologic Oncology Group study. J Clin Oncol. 1995;13:1589-1599.
18. Hoskins WJ, McGuire WP, Brady MF, et al. The effect of diameter of largest residual disease on survival after primary cytoreductive surgery in patients with suboptimal residual epithelial ovarian carcinoma. Am J Obstet Gynecol. 1994;170:974-979; discussion 9-80.
19. Jacobson GM, Kamath RS, Smith BJ, et al. Thromboembolic events in patients treated with definitive chemotherapy and radiation therapy for invasive cervical cancer. Gynecol Oncol. 2005;96:470-474. (Pubitemid 40127150)
20. Jacobson G, Lammli J, Zamba G, et al. Thromboembolic events in patients with cervical carcinoma: incidence and effect on survival. Gynecol Oncol. 2009;113:240-244.
21. Stewart SL, Wike JM, Foster SL, et al. The incidence of primary fallopian tube cancer in the United States. Gynecol Oncol. 2007;107:392-397. (Pubitemid 350160878)
22. Latzko W. Linkseitiges tubenkarzinom rechtseitige karzinomatose tuboovarial cyste. Zentralbl Gynakol. 1916;40:599.
23. Moore KN, Moxley KM, Fader AN, et al. Serous fallopian tube carcinoma: a retrospective, multi-institutional case-control comparison to serous adenocarcinoma of the ovary. Gynecol Oncol. 2007;107:398-403. (Pubitemid 350160880)
24. Le T, Adolph A, Krepart GV, et al. The benefits of comprehensive surgical staging in the management of early-stage epithelial ovarian carcinoma. Gynecol Oncol. 2002;85:351-355. (Pubitemid 34522997)
25. Gadducci A, Landoni F, Sartori E, et al. Analysis of treatment failures and survival of patients with fallopian tube carcinoma: a cooperation task force (CTF) study. Gynecol Oncol. 2001;81:150-159. (Pubitemid 32424153)
26. Pectasides D, Pectasides E, Papaxoinis G, et al. Primary fallopian tube carcinoma: results of a retrospective analysis of 64 patients. Gynecol Oncol. 2009;115:97-101.
27. Kosary C, Trimble EL. Treatment and survival for women with Fallopian tube carcinoma: a population-based study. Gynecol Oncol. 2002;86:190-191. (Pubitemid 34953503)
28. King A, Seraj IM, Thrasher T, et al. Fallopian tube carcinoma: a clinicopathological study of 17 cases. Gynecol Oncol. 1989;33:351-355. (Pubitemid 19148738)
29. Wolfson AH, Tralins KS, Greven KM, et al. Adenocarcinoma of the fallopian tube: results of a multi-institutional retrospective analysis of 72 patients. Int J Radiat Oncol Biol Phys. 1998;40:71-76. (Pubitemid 28027569)
30. Boronow RC. Fallopian tube cancer: radical surgery, extended field radiation and chemotherapy in 24 personal cases treated with "intent to cure". Gynecol Oncol. 2008;111:517-522.
31. Goodheart M, Jacobson G, Smith BJ, et al. Chemoradiation for invasive cervical cancer in elderly patients: outcomes and morbidity. Int J Gynecol Cancer. 2008;18:95-103.
32. Martino MA, Borges E, Williamson E, et al. Pulmonary embolism after major abdominal surgery in gynecologic oncology. Obstet Gynecol. 2006;107:666-671.
33. Chew HK, Wun T, Harvey D, et al. Incidence of venous thromboembolism and its effect on survival among patients with common cancers. Arch Intern Med. 2006;166:458-464.
34. Lee AY, Levine MN. Venous thromboembolism and cancer: risks and outcomes. Circulation. 2003;107:I17-21. (Pubitemid 41289267)
35. Alvarado-Cabrero I, Young RH, Vamvakas EC, et al. Carcinoma of the fallopian tube: a clinicopathological study of 105 cases with observations on staging and prognostic factors. Gynecol Oncol. 1999;72:367-379. (Pubitemid 29118195)
36. Jarvela I, Nuojua-Huttunen S, Martikainen H. Ovulation side and cycle fecundity: a retrospective analysis of frozen/ thawed embryo transfer cycles. Hum Reprod. 2000;15:1247-1249. (Pubitemid 30335944)
37. Bricou A, Batt RE, Chapron C. Peritoneal fluid flow influences anatomical distribution of endometriotic lesions: why Sampson seems to be right. Eur J Obstet Gynecol Reprod Biol. 2008;138:127-134. (Pubitemid 351735940)
38. Takeuchi K, Maruyama I, Yamamoto S, et al. Isolation and monolayer culture of human fallopian tube epithelial cells. In Vitro Cell Dev Biol. 1991;27A:720-724.
39. McMurray EH, Jacobs AJ, Perez CA, et al. Carcinoma of the fallopian tube. Management and sites of failure. Cancer. 1986;58:2070-2075. (Pubitemid 16008785)
40. Rustin GJ, van der Burg ME, Griffin CL, et al. Early versus delayed treatment of relapsed ovarian cancer (MRC OV05/EORTC 55955): a randomised trial. Lancet. 2010;376:1155-1163.
41. Cass I, Holschneider C, Datta N, et al. BRCA-mutation-associated fallopian tube carcinoma: a distinct clinical phenotype? Obstet Gynecol. 2005;106:1327-1334. (Pubitemid 41668953)
42. Friedman AJ, Ravnikar VA, Barbieri RL. Serum steroid hormone profiles in postmenopausal smokers and nonsmokers. Fertil Steril. 1987;47:398-401. (Pubitemid 17054207)
43. Bylander A, Nutu M, Wellander R, et al. Rapid effects of progesterone on ciliary beat frequency in the mouse fallopian tube. Reprod Biol Endocrinol. 2010;8:48.
44. Riska A, Sund R, Pukkala E, et al. Parity, tubal sterilization, hysterectomy and risk of primary fallopian tube carcinoma in Finland, 1975-2004. Int J Cancer. 2007;120:1351-1354.
45. Lee P, Rosen DG, Zhu C, et al. Expression of progesterone receptor is a favorable prognostic marker in ovarian cancer. Gynecol Oncol. 2005;96:671-677. (Pubitemid 40255486)
46. Kenfield SA, Stampfer MJ, Rosner BA, et al. Smoking and smoking cessation in relation to mortality in women. JAMA. 2008;299:2037-2047. (Pubitemid 351656585)
47. Aziz S, Kuperstein G, Rosen B, et al. A genetic epidemiological study of carcinoma of the fallopian tube. Gynecol Oncol. 2001;80:341-345. (Pubitemid 32207532)